Muehleman Deanna L, Crocini Claudia, Swearingen Alison R, Ozeroff Christopher D, Leinwand Leslie A
BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado.
Department of Molecular and Cellular Development, University of Colorado Boulder, Boulder, Colorado.
Am J Physiol Heart Circ Physiol. 2022 May 1;322(5):H785-H797. doi: 10.1152/ajpheart.00644.2021. Epub 2022 Mar 18.
Pathological cardiac hypertrophy is associated with increased morbidity and mortality. Understanding the mechanisms whereby pathological cardiac growth can be reversed could be of therapeutic value. Here, we show that pathways leading to regression of pathological cardiac hypertrophy are strongly dependent on the hypertrophic trigger and are significantly modified by sex. Two pathological stimuli causing hypertrophy via distinct pathways were administered to male and female mice: angiotensin II (ANG II) or isoproterenol (Iso). Stimuli were removed after 7 days of treatment, and left ventricles (LVs) were studied at 1, 4, and 7 days. ANG II-treated females did not show regression after stimulus removal. Iso-treated males showed rapid LV hypertrophy regression. Somewhat surprisingly, RNAseq analysis at after removal of triggers revealed only 45 differentially regulated genes in common among all the groups, demonstrating distinct responses. Ingenuity pathway analysis predicted strong downregulation of the TGFβ1 pathway in all groups except for ANG II-treated females. Consistently, we found significant downregulation of Smad signaling after stimulus removal including in ANG II-treated females. In addition, the ERK1/2 pathway was significantly reduced in the groups showing regression. Finally, protein degradation pathways were significantly activated only in Iso-treated males 1 day after stimulus removal. Our data indicate that TGFβ1 downregulation may play a role in the regression of pathological cardiac hypertrophy via downregulation of the ERK1/2 pathway and activation of autophagy and proteasome activity in Iso-treated males. This work highlights that the reversal of pathological hypertrophy does not use universal signaling pathways and that sex potently modifies this process. Pathological cardiac hypertrophy is a major risk factor for mortality and is thought to be largely irreversible in many individuals. Although cardiac hypertrophy itself has been studied extensively, very little is understood about its regression. It is important that we have a better understanding of mechanisms leading to regression, why this process is not reversible in some individuals and that sex differences need to be considered when contemplating therapies.
病理性心脏肥大与发病率和死亡率增加相关。了解病理性心脏生长得以逆转的机制可能具有治疗价值。在此,我们表明导致病理性心脏肥大消退的途径强烈依赖于肥大触发因素,并且会因性别而发生显著改变。通过不同途径导致肥大的两种病理性刺激物被施用于雄性和雌性小鼠:血管紧张素II(ANG II)或异丙肾上腺素(Iso)。治疗7天后去除刺激物,并在第1、4和7天对左心室(LV)进行研究。去除刺激物后,接受ANG II治疗的雌性小鼠未出现消退。接受Iso治疗的雄性小鼠显示左心室肥大迅速消退。有点令人惊讶的是,去除触发因素后进行的RNAseq分析显示,所有组中仅有45个差异调节基因相同,表明存在不同的反应。通路分析预测,除接受ANG II治疗的雌性小鼠外,所有组中TGFβ1通路均强烈下调。一致地,我们发现去除刺激物后Smad信号显著下调,包括接受ANG II治疗的雌性小鼠。此外,在显示消退的组中ERK1/2通路显著降低。最后,仅在去除刺激物1天后接受Iso治疗的雄性小鼠中,蛋白质降解途径被显著激活。我们的数据表明,TGFβ1下调可能通过下调ERK1/2通路以及激活接受Iso治疗的雄性小鼠的自噬和蛋白酶体活性,在病理性心脏肥大消退中发挥作用。这项工作强调,病理性肥大的逆转并非使用通用信号通路,并且性别有力地改变了这一过程。病理性心脏肥大是死亡的主要危险因素,并且在许多个体中被认为在很大程度上是不可逆的。尽管心脏肥大本身已被广泛研究,但对其消退了解甚少。重要的是,我们要更好地理解导致消退的机制、为什么这个过程在某些个体中不可逆,以及在考虑治疗时需要考虑性别差异。